Skip to content
DraconiticResearch
Search Sources API
194,216 studies31 sourcesUpdated 28 min ago
PreprintCC BY 4.0arXiv

Should the pharmaceutical industry consider using high-order autoregressive models when modelling panel data?

Abstract

Longitudinal data, often in the form of panel data, are commonly encountered in the pharmaceutical industry. However it is not always possible to fit an unstructured covariance matrix when using the Mixed Model for Repeated Measures (MMRM). Here we argue that high-order autoregressive models provide a useful framework when more general correlation structures, such as the unstructured and/or Toeplitz, are unfeasible. The autoregressive model of order one is often suggested but, in our experience, higher orders are seldom considered. We present the case for using autoregressive models, with potentially high orders, as a flexible framework to model correlations in panel data, when more general structures are hard to identify.

Related

  1. Scalable Sparse Autoregressive Variational Inference for Non-Gaussian Spatial Fields
    Paul F. V. Wiemann, Matthias Katzfuss
    arXivPreprintCC BY 4.0Full textStatisticsarXiv
  2. Estimating Great Expectations Under Autoregressive Language Models with Potentials
    Francesco I. Re, Shubhangi Ghosh, Tim Vieira +1
    arXivPreprintCC BY 4.0Full textStatisticsarXiv
  3. Bayesian spatiotemporal conditional autoregressive model for local temporal variations
    Takahiro Onizuka, Shintaro Hashimoto
    arXivPreprintarXiv licenceFull textStatisticsarXiv
  4. The natural components of an autoregressive time series on Banach space
    Phil Howlett, Brendan K Beare
    arXivPreprintCC BY 4.0Full textAnalysis & PDEsarXiv
  5. Realized Tail-Risk Conditional Autoregressive Expectile Models: Accurate and Stable Forecasting Performance
    Keisuke Sasaki, Yasuhiro Omori
    arXivPreprintarXiv licenceFull textStatisticsarXiv
BibTeX
@misc{jackson2026should,
  title = {{Should the pharmaceutical industry consider using high-order autoregressive models when modelling panel data?}},
  author = {Dan Jackson and Fanni Zhang and Abdul-Azeez Ganiyu and Rose Baker},
  howpublished = {arXiv},
  year = {2026},
  month = sep,
  doi = {10.48550/arxiv.2609.26405},
  eprint = {2609.26405},
  archivePrefix = {arXiv},
  url = {https://arxiv.org/abs/2609.26405},
  note = {CC BY 4.0},
}
RIS
TY  - UNPB
TI  - Should the pharmaceutical industry consider using high-order autoregressive models when modelling panel data?
AU  - Dan Jackson
AU  - Fanni Zhang
AU  - Abdul-Azeez Ganiyu
AU  - Rose Baker
PY  - 2026
DA  - 2026/09/22
PB  - arXiv
DO  - 10.48550/arxiv.2609.26405
UR  - https://arxiv.org/abs/2609.26405
AB  - Longitudinal data, often in the form of panel data, are commonly encountered in the pharmaceutical industry. However it is not always possible to fit an unstructured covariance matrix when using the Mixed Model for Repeated Measures (MMRM). Here we argue that high-order autoregressive models provide a useful framework when more general correlation structures, such as the unstructured and/or Toeplitz, are unfeasible. The autoregressive model of order one is often suggested but, in our experience, higher orders are seldom considered. We present the case for using autoregressive models, with potentially high orders, as a flexible framework to model correlations in panel data, when more general structures are hard to identify.
ER  -